<DOC>
	<DOCNO>NCT00003062</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effect temozolomide patient progressive recurrent stage IV non-small cell lung cancer , without brain metastasis , treat metastatic disease chemotherapy .</brief_summary>
	<brief_title>Temozolomide Patients With Progressive Recurrent Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess therapeutic activity temozolomide ( TMZ ) patient non-small cell lung cancer ( NSCLC ) without brain metastasis , untreated chemotherapy metastatic disease . II . Characterize acute side effect temozolomide patient . III . Assess duration response respond patient . OUTLINE : This open label , nonrandomized , multicenter study . Temozolomide give oral dos equally fractionate 5 day repeat every 4 week . Patients brain metastasis : Treatment discontinue progression disease site ( brain nonbrain ) progression disease brain lesion stable disease target lesion . Patients progressive disease brain target lesion contemporary evidence response target lesion receive temozolomide , addition nonchemotherapy medical treatment brain metastasis ( steroid , mannitol , etc. ) . Patients progressive disease target lesion contemporary evidence response brain target lesion receive temozolomide therapy , addition specific local radiotherapy nonbrain lesion . Patients without brain metastasis : Treatment discontinues clear cut progression occur first disease evaluation ( 8 week treatment start ) . For stable disease , patient treat minimum 8 week evaluate thereafter . Treatment , case , minimum 2 cycle may continue maximum 6 cycle absence disease progression , unacceptable toxicity , patient refusal . All patient follow every 6 week survival . PROJECTED ACCRUAL : A minimum 24 evaluable patient maximum 70 evaluable patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm progressive recurrent stage IV nonsmall cell lung cancer ( NSCLC ) Patient brain metastasis CT MRI scan include Symptomatic case must brain radiotherapy least one month prior registration Patients without brain metastasis : At least one target lesion Bidimensionally measurable Not previously irradiate PATIENT CHARACTERISTICS : Age : Under 70 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 2,000/mm3 WBC great 3,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.46 mg/dL Transaminases le 2 time upper limit normal Renal : Creatinine great 1.70 mg/dL Creatinine clearance great 60 mL/min Other : No prior concurrent malignancy sit exception adequately treat situ carcinoma cervix basal squamous carcinoma skin Not pregnant nursing Negative pregnancy test 24 hour prior commence temozolomide PRIOR CONCURRENT THERAPY : No investigational drug allow study Biologic therapy : Prior biologic therapy allow No concurrent biologic therapy allow No concurrent growth factor induce neutrophil increase No concurrent erythropoietin Chemotherapy : No prior chemotherapy metastatic disease At least 3 month since neoadjuvant adjuvant treatment , induction chemotherapy precede radical radiotherapy Endocrine therapy : See Protocol Outline Concurrent steroid maintain low dose possible Radiotherapy : Prior radiotherapy allow Concurrent local radiotherapy nonbrain lesion allow Concurrent palliative radiation therapy bone lesion permit No concurrent radiation target lesions No concurrent brain radiotherapy Surgery : Prior surgery allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>